7 days ago
ZIM Laboratories shares in focus as company gets first marketing approval in Australia
By Aditya Bhagchandani Published on July 21, 2025, 14:05 IST
ZIM Laboratories Limited announced that it has secured its first Marketing Authorization (MA) in Australia for its Central Nervous System (CNS) drug, Rizatriptan Benzoate Orally Disintegrating Films, through its Australian subsidiary ZIMTAS PTY LTD. The approval was granted by the Therapeutic Goods Administration (TGA), Australia, marking an important milestone in ZIM's strategy to expand in regulated markets with its innovative drug delivery technologies.
According to the company's filing with stock exchanges on July 21, 2025, this approval will facilitate the commercial launch of the product in the Australian market and serve as a platform for further regulatory filings across the Asia-Pacific region.
Rizatriptan, a selective 5-HT₁B/₁D receptor agonist, is indicated for the acute treatment of migraine attacks in adults. The novel orally disintegrating film (ODF) formulation developed using ZIM's proprietary technology platform offers a patient-friendly alternative by enabling rapid onset of action without water, which is particularly beneficial for patients experiencing nausea or vomiting during migraine episodes.
The company noted that this milestone: Enables immediate commercial entry into Australia via ZIMTAS.
Validates ZIM's oral thin film platform as a globally relevant drug delivery technology.
Opens avenues for further filings in the Asia-Pacific region.
Management highlighted that the approval is a testament to ZIM's focus on differentiated, technology-driven generics designed to enhance treatment adherence and improve patient experience.
ZIM Laboratories, a Nagpur-based, research-driven pharmaceutical company, specializes in differentiated generic oral solid dosage forms and is listed on both the BSE and NSE.
This development comes as part of ZIM's ongoing efforts to strengthen its presence in regulated international markets by leveraging its state-of-the-art R&D capabilities and proprietary drug delivery platforms.
Disclaimer: The information provided above is based on the company's stock exchange filing and press release. It is for informational purposes only and should not be construed as financial or investment advice. Stock market investments are subject to market risks. Please conduct your own research or consult a financial advisor before making any investment decisions. Neither the author nor the publisher is responsible for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
